Please use this identifier to cite or link to this item: http://hdl.handle.net/2381/44453
Full metadata record
DC FieldValueLanguage
dc.contributor.authorHaynes, R-
dc.contributor.authorJudge, PK-
dc.contributor.authorStaplin, N-
dc.contributor.authorHerrington, WG-
dc.contributor.authorStorey, BC-
dc.contributor.authorBethel, A-
dc.contributor.authorBowman, L-
dc.contributor.authorBrunskill, N-
dc.contributor.authorCockwell, P-
dc.contributor.authorHill, M-
dc.contributor.authorKalra, PA-
dc.contributor.authorMcMurray, JJV-
dc.contributor.authorTaal, M-
dc.contributor.authorWheeler, DC-
dc.contributor.authorLandray, MJ-
dc.contributor.authorBaigent, C-
dc.date.accessioned2019-06-17T13:33:40Z-
dc.date.available2019-06-17T13:33:40Z-
dc.date.issued2018-10-09-
dc.identifier.citationCirculation, 2018;138:1505–1514en
dc.identifier.issn0009-7322-
dc.identifier.urihttps://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.118.034818en
dc.identifier.urihttp://hdl.handle.net/2381/44453-
dc.descriptionThe online-only Data Supplement, podcast, and transcript are available with this article at https://www.ahajournals.org/doi/suppl/10.1161/CIRCULATIONAHA.118.034818.en
dc.description.abstractBackground: Sacubitril/valsartan reduces the risk of cardiovascular mortality among patients with heart failure with reduced ejection fraction, but its effects on kidney function and cardiac biomarkers in people with moderate to severe chronic kidney disease are unknown. Methods: The UK HARP-III trial (United Kingdom Heart and Renal Protection-III), a randomized double-blind trial, included 414 participants with an estimated glomerular filtration rate (GFR) 20 to 60 mL/min/1.73 m2 who were randomly assigned to sacubitril/valsartan 97/103 mg twice daily versus irbesartan 300 mg once daily. The primary outcome was measured GFR at 12 months using ANCOVA with adjustment for each individual’s baseline measured GFR. All analyses were by intention to treat. Results: In total, 207 participants were assigned to sacubitril/valsartan and 207 to irbesartan. Baseline measured GFR was 34.0 (SE, 0.8) and 34.7 (SE, 0.8) mL/min/1.73 m2, respectively. At 12 months, there was no difference in measured GFR: 29.8 (SE 0.5) among those assigned sacubitril/valsartan versus 29.9 (SE, 0.5) mL/min/1.73 m2 among those assigned irbesartan; difference, -0.1 (0.7) mL/min/1.73 m2. Effects were similar in all prespecified subgroups. There was also no significant difference in estimated GFR at 3, 6, 9, or 12 months and no clear difference in urinary albumin:creatinine ratio between treatment arms (study average difference, -9%; 95% CI, -18 to 1). However, compared with irbesartan, allocation to sacubitril/valsartan reduced study average systolic and diastolic blood pressure by 5.4 (95% CI, 3.4–7.4) and 2.1 (95% CI, 1.0–3.3) mm Hg and levels of troponin I and N terminal of prohormone brain natriuretic peptide (tertiary end points) by 16% (95% CI, 8–23) and 18% (95% CI, 11–25), respectively. The incidence of serious adverse events (29.5% versus 28.5%; rate ratio, 1.07; 95% CI, 0.75–1.53), nonserious adverse reactions (36.7% versus 28.0%; rate ratio, 1.35; 95% CI, 0.96–1.90), and potassium ≥5.5 mmol/L (32% versus 24%, P=0.10) was not significantly different between randomized groups. Conclusions: Over 12 months, sacubitril/valsartan has similar effects on kidney function and albuminuria to irbesartan, but it has the additional effect of lowering blood pressure and cardiac biomarkers in people with chronic kidney disease. Clinical Trial Registration: URL: http://www.isrctn.com. Unique identifier: ISRCTN11958993.en
dc.description.sponsorshipThe UK HARP-III trial was designed, conducted, and analyzed by the MRC Population Health Research Unit, which is part of the Clinical Trial Service Unit and Epidemiological Studies Unit. The University of Oxford was the independent regulatory sponsor for the study. The study was funded by a grant to the University of Oxford from Novartis (the manufacturer of sacubitril/valsartan). The funder had no involvement in the study conduct, analysis, or decision to submit for publication. The trial was supported by the Medical Research Council (which funds the Medical Research Council Population Health Research Unit in a strategic partnership with the University of Oxford) and the National Institute for Health Research Clinical Research Network.en
dc.language.isoenen
dc.publisherAmerican Heart Association, Lippincott, Williams & Wilkinsen
dc.rightsCopyright © the authors, 2018. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-commercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted use, distribution, and reproduction in any medium non-commercially, provided the original author and source are credited.en
dc.titleEffects of Sacubitril/Valsartan Versus Irbesartan in Patients with Chronic Kidney Disease: A Randomised Double-Blind Trialen
dc.typeJournal Articleen
dc.identifier.doi10.1161/CIRCULATIONAHA.118.034818-
dc.identifier.eissn1524-4539-
dc.description.statusPeer-revieweden
dc.description.versionPublisher Versionen
dc.type.subtypeArticle-
pubs.organisational-group/Organisationen
pubs.organisational-group/Organisation/COLLEGE OF LIFE SCIENCESen
pubs.organisational-group/Organisation/COLLEGE OF LIFE SCIENCES/School of Medicineen
pubs.organisational-group/Organisation/COLLEGE OF LIFE SCIENCES/School of Medicine/Department of Infection, Immunity and Inflammationen
pubs.organisational-group/Organisation/COLLEGE OF LIFE SCIENCES/Themesen
pubs.organisational-group/Organisation/COLLEGE OF LIFE SCIENCES/Themes/Cardiovascularen
pubs.organisational-group/Organisation/COLLEGE OF LIFE SCIENCES/Themes/Molecular & Cellular Bioscienceen
dc.dateaccepted2018-06-22-
Appears in Collections:Published Articles, Dept. of Infection, Immunity and Inflammation

Files in This Item:
File Description SizeFormat 
CIRCULATIONAHA.118.034818.pdfPublished (publisher PDF)255.55 kBAdobe PDFView/Open


Items in LRA are protected by copyright, with all rights reserved, unless otherwise indicated.